Production (Stage)
Leap Therapeutics, Inc.
LPTX
$0.393
-$0.0022-0.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.04% | 16.74% | 20.31% | 27.10% | 38.00% |
| Total Depreciation and Amortization | -19.05% | -733.33% | -706.67% | 53.68% | -800.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.80% | -82.08% | -86.50% | -85.42% | -85.29% |
| Change in Net Operating Assets | 159.90% | -48.63% | 609.96% | 416.79% | 394.25% |
| Cash from Operations | -27.26% | -37.82% | -18.93% | -3.95% | 7.28% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 66.70% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -100.00% | -100.00% | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -100.00% | -100.00% | -100.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 138,241.38% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -10,065.52% | -10,065.52% | -9,837.93% | 100.00% |
| Cash from Financing | 132,378.57% | 124,046.67% | 123,700.00% | 128,186.21% | 196.55% |
| Foreign Exchange rate Adjustments | 82.89% | -548.84% | 242.74% | 89.84% | 6.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.87% | -554.87% | -835.93% | -2,531.58% | -3,886.21% |